• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·Sweden·Technology·ORTI-B.ST
Share

Ortivus AB (publ) Stocks

SEK 1.54Last Updated 05.10.2026

Issuer Rating

1/7
Performance

Modest

Risk

High

Recommendation

Sell

Market Cap

SEK 13.19M

SEK 1.54
Key Takeaways

Risk factor

Very high price volatility

Data is available to registered users only
Data is available to registered users only

Profitability factor

Very low or no dividends

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Ortivus AB (publ) develops and commercializes medical technology solutions and e-health for healthcare industry in Sweden and internationally. The company offers MobiMed Monitor that monitor and shares vital signs and ECG; MobiMed ePR, an electronic patient record system for documentation of treatment and events; MobiMed enRoute, a navigation, case management, and mass casualty management; MobiMed FleetCtrl, a a software application that regular controls, checklists, and documentation tailored for seamless fleet management; MobiMed Life, a heart safe solution. It also provides ambulance services, primary care, and rescue services. The company was incorporated in 1985 and is headquartered in Danderyd, Sweden. Ortivus AB (publ) is a subsidiary of Ponderus Invest AB.

Company Valuation

Overvalued
2/7

Based on key historical and expected multiples, the stock is overvalued relative to its peers.

Data is available to registered users only
Sign up to access detailed valuation

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

09.10.2026 19:00

Shares of luxury brands have fallen 25% this year. When can we expect a turnaround, and which ones should we bet on?

09.10.2026 18:49

U.S. stocks rebounded after two days of declines: Is the AI rally continuing?

09.10.2026 17:48

Data center optics are sold out for the next two years — Lumentum. Who else is seeing gains?

09.10.2026 17:26

Deeply Unpopular Stocks: Strategist Recommends Stocks to Ride Out the Sell-Off

09.10.2026 17:15

Shares of biotech company Pacira soared 44%: the maker of "Viagra" is set to acquire it

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026